摘要
IL-2是由活化T细胞产生的白介素家族成员之一,可以通过与细胞表面的白介素2受体结合而刺激T细胞的增殖、发育和分化。不同种类的T细胞对IL-2的敏感性不同,调节性T细胞(regulatory T cell,Treg)对IL-2的敏感性高于其它细胞。所以,低剂量的IL-2可以在不影响效应T细胞(effector T cell,Teff)的情况下,选择性激活Treg信号通路,调节Treg的细胞水平和功能,增强免疫抑制反应,进行免疫调控。目前,低剂量IL-2(low-doses IL-2,LdIL-2)在一些自身免疫疾病治疗研究中得到广泛关注。本文就低剂量IL-2治疗自身免疫性疾病的研究进展作一简要论述。
IL-2, a member of interleukin family, is produced by activated T cells. IL-2 can stimulate the T cell proliferation, development, and differentiation after binding to the IL-2 receptor. The sensitivity to IL-2 varies in different types of T cells. Regulatory T cells(Treg) are more sensitive to IL-2 than other effector T cells do. Lowdoses of IL-2(LdIL-2) can activate the signal pathway of the Treg cell without affecting the effector T cells, and regulates the proliferation and function of the Treg cells, as well as enhances the immunosuppressive response. At present, significant insight has been made in the treatment of LdIL-2 for some autoimmune diseases. This article reviews the progress of LdIL-2 in the treatment of autoimmune diseases.
作者
张小娟
苏丽丽
孙剑
ZHANG Xiaojuan;SU Lili;SUN Jian(School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China)
出处
《免疫学杂志》
CAS
CSCD
北大核心
2019年第6期543-548,共6页
Immunological Journal
基金
国家自然科学基金(81273308)
